Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2022-02-07 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1917 characters) and contains the header 'RNS Number : 9373A'. It announces a 'Price Monitoring Extension' for a security, which is a specific, non-financial operational update related to trading on the London Stock Exchange. The text explicitly mentions 'RNS, the news service of the London Stock Exchange' and that RNS is approved to act as a Primary Information Provider. This type of brief, operational regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2022-02-07 English
Issue of Equity and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is clearly identified as an 'RNS Number' release from 'Avacta Group PLC' dated '03 February 2022'. The subject is 'Issue of Equity and Total Voting Rights', detailing the allotment of new ordinary shares and the resulting enlarged issued share capital. This type of announcement, concerning changes in share capital or issuance of shares, directly corresponds to the 'Share Issue/Capital Change' definition. Therefore, the appropriate code is SHA.
2022-02-03 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1934 characters) and contains the header 'RNS Number : 6623A' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, time-sensitive market announcement. This type of general regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category, RNS (Regulatory Filings), as per the definitions and the 'Menu vs Meal' rule suggesting short announcements default to RNS/RPA if they aren't the primary report.
2022-02-03 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1917 characters) and contains the header 'RNS Number : 6603A'. It announces a 'Price Monitoring Extension' related to trading rules on the London Stock Exchange. The text explicitly mentions that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the Financial Conduct Authority (FCA). This structure—a brief, specific operational announcement distributed via the RNS system—fits best under the general 'Regulatory Filings' category, as it is not a core financial report (like 10-K, IR, ER) nor a specific corporate action like a dividend or management change. It is a miscellaneous regulatory update distributed through the official channel.
2022-02-03 English
Dose escalation in the phase I trial of AVA6000
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated '03 February 2022'. It announces a specific corporate event: 'Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin'. The text includes disclosures related to Market Abuse Regulation (MAR) and is distributed via RNS, the news service of the London Stock Exchange. This structure—a brief, timely announcement of material, non-public information distributed through an official news service—is characteristic of a general regulatory announcement that doesn't fit the more specific categories like 10-K, ER, or CT. Since it is a general regulatory announcement provided via RNS, the most appropriate fallback category is Regulatory Filings (RNS). The document length is substantial (8097 chars), so it is not an RPA, but a substantive announcement itself.
2022-02-03 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1933 characters) and contains the header 'RNS Number : 2078A' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, short-form regulatory market announcement related to trading halts or price volatility. This type of brief, immediate market notification that doesn't fit into the specific financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing (RNS). It is not an announcement of a report (RPA), but a direct regulatory update.
2022-01-31 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.